TABLE 4.
Appropriateness of antibiotic therapy in patients receiving or not receiving aminoglycosides as empirical therapy
| Microorganism | No./total no. (%) receiving: |
OR (95% CI) | P | |
|---|---|---|---|---|
| Combination | β-Lactam | |||
| Non-ESBL E. coli | 242/248 (98) | 2,454/2,489 (99) | 0.6 (0.2-1.7) | 0.3 |
| ESBL E. coli | 21/28 (75) | 62/122 (51) | 2.9 (1.07-8.2) | 0.02 |
| Non-ESBL K. pneumoniae | 62/63 (98) | 393/420 (94) | 4 (0.7-177) | 0.2 |
| ESBL K. pneumoniae | 18/20 (90) | 38/63 (60) | 2 (1.2-4.2) | 0.01 |
| P. mirabilis | 10/10 (100) | 116/118 (98) | 1 | |
| Salmonella spp. | 15/15 (100) | 108/109 (99) | 1 | |
| AmpC organisms | 78/82 (95) | 258/326 (79) | 5.1 (1.8-20) | 0.001 |
| P. aeruginosa | 133/143 (93) | 201/319 (63) | 7.8 (3.8-16) | <0.0001 |
| Other nonfermenters | 24/51 (47) | 53/105 (51) | 0.9 (0.4-1.8) | 0.7 |
| Miscellaneous | 18/18 (100) | 105/114 (92) | 0.4 | |